Our findings suggest that the combination of chemotherapy, immunotherapy, and anti-angiogenic agents may represent a viable therapeutic strategy for patients with <i>KRAS</i> G13C/<i>TP53</i> co-mutated NSCLC. Here, KRAS is linked to non-small cell lung carcinoma.